The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bevacizumab Monoclonal Antibody Biosimilar Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029
Synopsis
The global Bevacizumab Monoclonal Antibody Biosimilar market size was valued at USD 1379.8 million in 2022 and is forecast to a readjusted size of USD 484.9 million by 2029 with a CAGR of -13.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
This report is a detailed and comprehensive analysis for global Bevacizumab Monoclonal Antibody Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Bevacizumab Monoclonal Antibody Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bevacizumab Monoclonal Antibody Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bevacizumab Monoclonal Antibody Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bevacizumab Monoclonal Antibody Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bevacizumab Monoclonal Antibody Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bevacizumab Monoclonal Antibody Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion, Amneal, Pfizer and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Bevacizumab Monoclonal Antibody Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
400mg
100mg
Market segment by Application
Cancer
Wet Age-related Macular Degeneration
Other
Major players covered
Celltrion
Amneal
Pfizer
Amgen
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bevacizumab Monoclonal Antibody Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, with price, sales, revenue and global market share of Bevacizumab Monoclonal Antibody Biosimilar from 2018 to 2023.
Chapter 3, the Bevacizumab Monoclonal Antibody Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bevacizumab Monoclonal Antibody Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Bevacizumab Monoclonal Antibody Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bevacizumab Monoclonal Antibody Biosimilar.
Chapter 14 and 15, to describe Bevacizumab Monoclonal Antibody Biosimilar sales channel, distributors, customers, research findings and conclusion.
The global Bevacizumab Monoclonal Antibody Biosimilar market size was valued at USD 1379.8 million in 2022 and is forecast to a readjusted size of USD 484.9 million by 2029 with a CAGR of -13.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Avastin Biosimilar is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
This report is a detailed and comprehensive analysis for global Bevacizumab Monoclonal Antibody Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Bevacizumab Monoclonal Antibody Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bevacizumab Monoclonal Antibody Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bevacizumab Monoclonal Antibody Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Bevacizumab Monoclonal Antibody Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bevacizumab Monoclonal Antibody Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bevacizumab Monoclonal Antibody Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion, Amneal, Pfizer and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Bevacizumab Monoclonal Antibody Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
400mg
100mg
Market segment by Application
Cancer
Wet Age-related Macular Degeneration
Other
Major players covered
Celltrion
Amneal
Pfizer
Amgen
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bevacizumab Monoclonal Antibody Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bevacizumab Monoclonal Antibody Biosimilar, with price, sales, revenue and global market share of Bevacizumab Monoclonal Antibody Biosimilar from 2018 to 2023.
Chapter 3, the Bevacizumab Monoclonal Antibody Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bevacizumab Monoclonal Antibody Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Bevacizumab Monoclonal Antibody Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bevacizumab Monoclonal Antibody Biosimilar.
Chapter 14 and 15, to describe Bevacizumab Monoclonal Antibody Biosimilar sales channel, distributors, customers, research findings and conclusion.
Index1 Market Overview
1.1 Product Overview and Scope of Bevacizumab Monoclonal Antibody Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 400mg
1.3.3 100mg
1.4 Market Analysis by Application
1.4.1 Overview: Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Wet Age-related Macular Degeneration
1.4.4 Other
1.5 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size & Forecast
1.5.1 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Celltrion
2.1.1 Celltrion Details
2.1.2 Celltrion Major Business
2.1.3 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.1.4 Celltrion Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Celltrion Recent Developments/Updates
2.2 Amneal
2.2.1 Amneal Details
2.2.2 Amneal Major Business
2.2.3 Amneal Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.2.4 Amneal Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amneal Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.3.4 Pfizer Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments/Updates
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Bevacizumab Monoclonal Antibody Biosimilar Product and Services
2.4.4 Amgen Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Amgen Recent Developments/Updates
3 Competitive Environment: Bevacizumab Monoclonal Antibody Biosimilar by Manufacturer
3.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Bevacizumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Bevacizumab Monoclonal Antibody Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Bevacizumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Bevacizumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.5 Bevacizumab Monoclonal Antibody Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Bevacizumab Monoclonal Antibody Biosimilar Market: Region Footprint
3.5.2 Bevacizumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
3.5.3 Bevacizumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region
4.1.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2029)
4.2 North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.5 South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Bevacizumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
7.3.1 North America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
8.3.1 Europe Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Market Size by Region
9.3.1 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
10.3.1 South America Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Market Size by Country
11.3.1 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Bevacizumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Bevacizumab Monoclonal Antibody Biosimilar Market Drivers
12.2 Bevacizumab Monoclonal Antibody Biosimilar Market Restraints
12.3 Bevacizumab Monoclonal Antibody Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Bevacizumab Monoclonal Antibody Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bevacizumab Monoclonal Antibody Biosimilar
13.3 Bevacizumab Monoclonal Antibody Biosimilar Production Process
13.4 Bevacizumab Monoclonal Antibody Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bevacizumab Monoclonal Antibody Biosimilar Typical Distributors
14.3 Bevacizumab Monoclonal Antibody Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
